| Description |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmedic |
|
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
| Product Type |
Product Size |
| Tablets |
28'S |
| Product Company |
| Himmel Pharma |
Bicalutamide 50mg |
| Product Type |
Product Size |
| Tablets |
30'S |
| Product Company |
| Beacon Pharmaceuticals |
Sorafenib 200mg |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Martin Dow |
Anastrozole 1mg |
| Product Type |
Product Size |
| Tablet |
60'S |
| Product Company |
| Pharma Solution |
Erlotinib 150mg |
| Content | Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. | Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. | Bicalutamide belongs to the group of medicines called antiandrogens. It works by blocking the effects of testosterone (a male hormone), which helps stop the growth and spread of cancer cells.
| Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body. Sorafenib is an antineoplastic (cancer) agent.
| Anastrozole is a type of hormone treatment. It works by lowering the levels of oestrogen hormones in your body. It is mainly prescribed for women who have been through the menopause and have a type of cancer called hormone-dependent breast cancer. | Erlotinib is an EGFR tyrosine kinase inhibitor used to treat certain small cell lung cancers or advanced metastatic pancreatic cancers. |
Reviews
There are no reviews yet.